Corrected: Entrada raises $100M for Duchenne development; eFFECTOR winds down
Plus, news about NeuroBo, Vico Therapeutics, Takeda, Checkpoint Therapeutics, CombiGene, Spark Therapeutics, ANI, Alimera Sciences and OSE Immunotherapeutics:
Entrada Therapeutics raises $100M from stock sale …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.